Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month Low – Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hit a new 52-week low on Tuesday . The company traded as low as $12.14 and last traded at $12.74, with a volume of 2848318 shares traded. The stock had previously closed at $13.82.

Wall Street Analysts Forecast Growth

ARWR has been the topic of several analyst reports. B. Riley reiterated a “buy” rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Stock Down 7.8 %

The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -2.46 and a beta of 0.92. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company’s 50 day moving average price is $17.99 and its 200 day moving average price is $19.55.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 11,520 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00. Following the completion of the transaction, the chief executive officer now directly owns 3,764,252 shares in the company, valued at $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 27,167 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the sale, the chief financial officer now directly owns 473,433 shares in the company, valued at $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 286,317 shares of company stock worth $5,049,735 over the last quarter. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ARWR. Mackenzie Financial Corp purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $137,000. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $49,000. Neo Ivy Capital Management purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $318,000. Two Sigma Advisers LP raised its position in shares of Arrowhead Pharmaceuticals by 330.7% in the fourth quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company’s stock worth $8,097,000 after acquiring an additional 330,700 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company’s stock worth $14,934,000 after acquiring an additional 586,062 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.